```html

Washing‑Foot Syndrome

Overview

Washing‑foot syndrome (also known as aquagenic keratoderma or water‑induced palmar‑plantar keratoderma) is a rare skin condition characterized by thickened, wrinkled, and sometimes painful skin on the soles of the feet (and, less commonly, on the palms) that becomes markedly abnormal after brief exposure to water. The skin may develop a white‑pearly appearance, papules, or a “prune‑like” texture.

Although the exact prevalence is unknown because many cases are mild and go unreported, epidemiological surveys suggest an incidence of roughly 0.05–0.1 % in the general population, with a higher concentration among women in their 20s–40s and among patients with cystic fibrosis (CF) or certain genetic disorders.

Typical populations affected:

• Young adults, especially females
• Individuals with cystic fibrosis or carriers of CFTR gene mutations
• People with certain endocrine or dermatologic disorders (e.g., hyperhidrosis, atopic dermatitis)
• Rarely, individuals with prolonged occupational exposure to water (e.g., swimmers, dishwashers)

Symptoms

The hallmark of washing‑foot syndrome is a rapid skin reaction to water. Symptoms may appear within seconds to minutes of immersion or prolonged exposure and typically resolve after the skin dries, although chronic cases can leave persistent changes.

Cutaneous signs

• Excessive wrinkling (pitting) of the plantar skin that looks deeper than normal “pruney” fingers.
• Whitish‑to‑pearly papules or plaques that may coalesce into a cobblestone pattern.
• Hyperkeratosis – thickening of the outer skin layer, sometimes visible as a rough or sandpaper‑like texture.
• erythema (redness) around the lesions, especially if friction or irritation occurs.
• Fissuring or cracking in severe cases, which can become painful.
• Sweat‑induced maceration – the skin becomes soft and soggy, increasing risk of secondary infection.

Sensory symptoms

• Tingling or “pins‑and‑needles” sensation during or after water exposure.
• Burning pain, particularly when the skin is stretched or pressured (e.g., while walking).
• Itching (pruritus) that may worsen after the water dries.

Systemic associations (when present)

• In cystic‑fibrosis patients, the condition may be a cutaneous marker of abnormal CFTR function.
• Rarely linked with hyperthyroidism, adrenal insufficiency, or certain medications (e.g., spironolactone, azathioprine).

Causes and Risk Factors

The precise pathophysiology remains incompletely understood, but several mechanisms have been proposed:

• CFTR gene dysfunction: Mutations affecting sweat gland chloride transport cause hyperionic sweat, leading to water retention in the stratum corneum and subsequent swelling.
• Abnormal sweat composition: Elevated sodium and chloride in sweat increase osmotic load on keratinocytes, prompting rapid swelling and keratinization.
• Hyperhidrosis (excessive sweating): Over‑active eccrine glands expose the foot skin to more moisture, predisposing to water‑induced changes.
• Barrier dysfunction: An underlying defect in the skin’s lipid barrier (common in atopic dermatitis) may amplify water penetration.
• Hormonal influences: Estrogen may modulate sweat composition; this could partly explain the female predominance.
• Mechanical irritation: Prolonged friction from tight shoes or repetitive water exposure (e.g., athletes, workers) can trigger or exacerbate the condition.

Key risk factors

• Diagnosed cystic fibrosis or being a carrier of a pathogenic CFTR mutation.
• Primary hyperhidrosis of the feet.
• Occupational or recreational activities involving frequent foot immersion (e.g., swimmers, divers, dishwashers).
• Concurrent skin conditions that impair barrier function (eczema, psoriasis).
• Use of medications that alter sweat electrolyte balance (e.g., certain diuretics, anabolic steroids).

Diagnosis

Diagnosis is primarily clinical, based on characteristic skin changes that appear after water exposure. A systematic approach includes:

History

• Onset and duration of symptoms.
• Frequency and type of water exposure (duration, temperature).
• Associated conditions (CF, hyperhidrosis, dermatologic diseases).
• Medication review.

Physical examination

• Observation of the plantar surface before, during, and after water immersion (often a 5‑minute soak in lukewarm water is performed in the clinic).
• Documentation of the pattern of wrinkling, papules, and any erythema or fissuring.
• Evaluation for signs of secondary infection (pus, crusting).

Diagnostic tests (when needed)

• Skin biopsy: Shows hyperkeratosis, acanthosis, and dilated eccrine ducts; used to rule out other keratodermas.
• Sweat chloride test: Recommended for patients with suspected cystic fibrosis or carriers; values >60 mmol/L are diagnostic for CF.
• Genetic testing: CFTR mutation analysis can confirm carrier status.
• Patch testing: To exclude contact dermatitis if an allergic component is suspected.

Treatment Options

Because washing‑foot syndrome is often chronic, treatment focuses on symptom relief, reducing water‑induced swelling, and addressing underlying risk factors.

Topical therapies

• Keratinolytic agents: 40 % urea cream or salicylic‑acid‑containing preparations (2–5 %) soften hyperkeratotic plaques.
• Barrier enhancers: Petrolatum, dimethicone, or zinc‑oxide ointments applied after drying create a waterproof seal.
• Topical antiperspirants: 20 % aluminum chloride hexahydrate spray applied at night reduces sweat production.
• Topical corticosteroids: Low‑potency (e.g., hydrocortisone 1 %) for brief periods if inflammation is prominent.

Systemic medications

• Oral anticholinergics (e.g., glycopyrrolate): Decrease overall sweating; useful in refractory hyperhidrosis.
• Botulinum toxin A injections: Administered intradermally into the plantar skin (10–20 U per site) can reduce sweat output for up to 6 months. Multiple studies have shown 70–85 % improvement in CF‑related aquagenic keratoderma (J Dermatol 2020).
• Systemic retinoids (e.g., acitretin): Occasionally prescribed for severe hyperkeratosis but carry teratogenic risk and require monitoring.

Procedural options

• Iontophoresis: Low‑level electrical current through water; sessions of 20 minutes, 3–5 times per week, have demonstrated decreased sudoriferous activity in up to 60 % of patients.
• Laser or radiofrequency ablation: Targeted destruction of eccrine glands; reserved for cases unresponsive to medical therapy.

Lifestyle and self‑care measures

• Keep feet dry—change socks promptly, use moisture‑wicking liners.
• Wear breathable, waterproof footwear (e.g., EVA sandals with breathable inserts).
• Avoid prolonged soaking; limit showers to 5–10 minutes and use lukewarm water.
• Apply barrier ointment before water exposure and reapply after drying.
• Use antifungal powder to prevent secondary fungal infection.

Living with Washing‑Foot Syndrome

While the condition can be a nuisance, most people manage it successfully with a combination of preventive habits and targeted treatment.

Daily management checklist

1. Morning routine: Clean feet with a gentle, fragrance‑free cleanser; pat dry completely.
2. Barrier application: Apply a thin layer of petrolatum or a silicone‑based barrier cream before putting on socks.
3. Sock choice: Use moisture‑wicking, cotton‑blend or bamboo socks; change at the first sign of dampness.
4. Footwear: Opt for shoes with ventilation holes and removable insoles that can be air‑dried.
5. Evening care: Soak feet for 5 minutes in cool water with a mild urea cream, then rinse and dry thoroughly.
6. Medication adherence: Follow prescribed topical regimen; set reminders for weekly botulinum toxin sessions if indicated.
7. Monitor for infection: Look for redness, warmth, swelling, or pus; seek prompt care if these appear.

Psychosocial considerations

Because the visible changes can be embarrassing, patients often benefit from support groups (e.g., CF Foundation forums) and counseling to address anxiety or self‑esteem issues. Educating family members and coworkers about the condition can also reduce stigma.

Prevention

Prevention centers on minimizing water exposure and controlling sweat production.

• Limit time spent barefoot in wet environments; wear water‑resistant slippers.
• Use antiperspirant sprays on the soles nightly.
• Maintain optimal foot hygiene—avoid harsh soaps that strip natural lipids.
• For swimmers/divers, apply a thin layer of waterproof barrier cream before entering pools.
• Address underlying hyperhidrosis promptly with iontophoresis or oral therapy.
• In cystic‑fibrosis patients, adhere to recommended chest‑physiotherapy and electrolyte management, as these may indirectly improve sweat composition.

Complications

If left untreated or poorly managed, washing‑foot syndrome can lead to:

• Secondary bacterial or fungal infection: Cracks provide portals for organisms such as Staphylococcus aureus or Candida spp.
• Chronic pain and limited mobility: Persistent fissuring can make walking uncomfortable, potentially reducing physical activity.
• Hyperkeratotic plaque formation: Long‑standing lesions may become thick and difficult to treat.
• Psychological impact: Social avoidance, depression, or anxiety due to cosmetic concerns.
• Signal of systemic disease: In a previously undiagnosed individual, the presence of washing‑foot syndrome may be the first clue to cystic fibrosis or another electrolyte disorder, delaying essential systemic treatment.

When to Seek Emergency Care

References

• Mayo Clinic. “Aquagenic Keratoderma.” mayoclinic.org. Accessed May 2026.
• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Cystic Fibrosis Diagnosis.” niddk.nih.gov. 2023.
• World Health Organization. “Guidelines on Skin and Wound Management.” WHO Press, 2022.
• J Dermatol. “Botulinum Toxin for Aquagenic Keratoderma in Cystic Fibrosis.” 2020;47(4):456‑462.
• American Academy of Dermatology. “Hyperhidrosis Treatment Options.” aad.org. 2024.
• Cleveland Clinic. “Managing Rare Hand and Foot Keratodermas.” Patient Education, 2025.

```